AMENDMENT TO THE DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT BETWEEN WYETH, ACTING THROUGH ITS WYETH CONSUMER HEALTHCARE DIVISION, AND IMPAX LABORATORIES, INC.Development, License and Supply Agreement • August 9th, 2004 • Impax Laboratories Inc • Pharmaceutical preparations
DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT dated as of June 18, 2002 between WYETH acting through its Wyeth Consumer Healthcare Division and IMPAX LABORATORIES, INC. for Loratadine/Pseudoephedrine Combination TabletsDevelopment, License and Supply Agreement • January 14th, 2009 • Impax Laboratories Inc • Pharmaceutical preparations • New York
THIS DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT is made and entered into as of this 1st day of June 2002, between WYETH, a corporation organized and existing under the laws of Delaware, acting through its Wyeth Consumer Healthcare Division and having an address at Five Giralda Farms, Madison, New Jersey 07940 (“WCH”) and IMPAX LABORATORIES, INC., a corporation organized and existing under the laws of Delaware and having an address at 3735 Castor Avenue, Philadelphia, Pennsylvania 19124 (“IMPAX”).
DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT Dated as of January 27, 2000 between EURAND AMERICA, NC. Vandalia, Ohio 45377 and RELIANT PHARMACEUTICALS New York, NY 10019 for EXTENDED RELEASE PROPRANOLOLDevelopment, License and Supply Agreement • October 26th, 2007 • Reliant Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT, dated as of January 27, 2000, between EURAND AMERICA, INC., a corporation organized under the laws of Nevada, with its principal offices at 845 Center Drive, Vandalia, Ohio 45377 (“EURAND”), and RELIANT PHARMACEUTICALS, INC., a corporation organized under the laws of the State of Delaware, with its principal offices at 125 West 55th Street, 11th floor, New York, New York (“RELIANT”);
AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • March 31st, 2023 • OS Therapies Inc • Pharmaceutical preparations • New York
This Amended and Restated Development, License and Supply Agreement (this “Agreement”) is entered into as of November 13, 2020 (the “Amendment Effective Date”), by and between Advaxis, Inc., a corporation organized under the laws of the State of Delaware, having an address of 305 College Road East, Princeton, NJ 08540 (“Advaxis”), and OS Therapies Incorporated, a corporation organized under the laws of the State of Delaware, having an address of 104 Tech Park Drive Cambridge, MD 21613 (“OST”). Advaxis and OST are each a “party” and, collectively, the “parties.”
RECITALSDevelopment, License and Supply Agreement • September 5th, 2002 • Gen Probe Inc • Services-commercial physical & biological research • New York
AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT by and between CIMA LABS INC. And ALAMO PHARMACEUTICALS, LLC dated as of August 22, 2005Development, License and Supply Agreement • November 9th, 2011 • Azur Pharma Public LTD Co • Pharmaceutical preparations • New York
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
EX-10.29 3 d642244dex1029.htm EX-10.29 DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • May 5th, 2020 • Delaware
THIS DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT (this “Agreement”) is made and entered into as of the latest dated signature on the signature page hereto (the “Effective Date”), and is by and between Watson Laboratories, Inc., a Nevada corporation (“Actavis”), on the one hand, and Merrimack Pharmaceuticals, Inc., a Delaware corporation (“Merrimack”), on the other hand. Actavis and Merrimack shall each sometimes be referred to herein as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • August 6th, 2010 • Inspire Pharmaceuticals Inc • Pharmaceutical preparations
This First Amendment to Development, License and Supply Agreement dated as of June 3, 2010 (this “Amendment”), is entered into by and between Inspire Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, having offices located at 4222 Emperor Boulevard, Suite 200, Durham, North Carolina 27703, USA (“Inspire”), and Santen Pharmaceutical Co., Ltd., a corporation organized under the laws of Japan, having offices located at 3-9-19 Shimoshinjo, Higashiyodogawa-ku, Osaka, 533-8651, Japan (“Santen”).
INTRODUCTIONDevelopment, License and Supply Agreement • April 7th, 2000 • Schein Pharmaceutical Inc • Pharmaceutical preparations
AMENDMENT TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • August 14th, 2000 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Illinois
DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • November 5th, 2009 • Gen Probe Inc • Surgical & medical instruments & apparatus • New York
This DEVELOPMENT, LICENSE, AND SUPPLY AGREEMENT (the “Agreement”) is entered into as of the 16th day of October, 2000 (the “Effective Date”) by and between GEN-PROBE INCORPORATED, a Delaware corporation having a principal place of business at 10210 Genetic Center Drive, San Diego, California 92121 (“Gen-Probe”), and KMC SYSTEMS, INC., a Delaware corporation having a principal place of business at 220 Daniel Webster Highway, Merrimack, New Hampshire (“KMC”), with reference to the following:
AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT by and between CIMA LABS INC. and ALAMO PHARMACEUTICALS, LLC dated as of August 22, 2005Development, License and Supply Agreement • August 9th, 2006 • Avanir Pharmaceuticals • Pharmaceutical preparations • New York
This AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT (this “Agreement”), dated and effective as of August 22, 2005 (the “Effective Date”), is by and between CIMA LABS INC., a Delaware corporation (“CIMA”), and ALAMO PHARMACEUTICALS, LLC, a California Limited Liability Company (“Alamo”).
AMENDMENT NUMBER 4 TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • March 31st, 2008 • Jazz Pharmaceuticals Inc • Pharmaceutical preparations
WHEREAS, Elan Corporation plc, an Irish company, and Solvay Pharmaceuticals, Inc., a Georgia corporation, entered into a development, license and supply agreement dated December 22, 1997, as amended by Amendment No. 1 dated March 1, 1999, Amendment No. 2 dated April 13, 2000 and Amendment No. 3 dated November 7, 2006 (collectively the “Development, License and Supply Agreement”).
FIRST AMENDMENT TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • February 27th, 2015 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS FIRST AMENDMENT TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT (this “Amendment”) is made and entered into as of the latest dated signature on the signature page hereto, and is by and between Watson Laboratories, Inc., a Nevada corporation (“Actavis”), on the one hand, and Merrimack Pharmaceuticals, Inc., a Delaware corporation (“Merrimack”), on the other hand. Actavis and Merrimack shall be referred to herein collectively as the “Parties.”
DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT THIS DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT (this "Agreement"), dated as of December 16, 1998, is entered into by and between Inspire Pharmaceuticals, Inc., a corporation organized and existing under the...Development, License and Supply Agreement • August 2nd, 2000 • Inspire Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
FIRST AMENDMENT TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • March 1st, 2013 • Endo Health Solutions Inc. • Pharmaceutical preparations
This First Amendment to Development, License and Supply Agreement (this “Amendment”) is entered into as of December 19, 2012 (“Date of Amendment”) by and between ENDO PHARMACEUTICALS INC., a Delaware corporation, with its principal offices located at 100 Endo Boulevard, Chadds Ford, Pennsylvania 19317, United States of America (“ENDO”) and Grünenthal GMBH, a company having its principal office at Zieglerstraße 6, 52078 Aachen, Federal Republic of Germany (“GRÜNENTHAL”). ENDO and GRÜNENTHAL may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Agreement.
FIRST AMENDMENT TO AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • April 24th, 2023 • OS Therapies Inc • Pharmaceutical preparations
This First Amendment to the Amended and Restated Development, License and Supply Agreement (this “Amendment”) between OS Therapies Incorporated, a corporation organized under the laws of the State of Delaware, having an address of 104 Tech Park Drive Cambridge, MD 21613 (the “Company”) and Advaxis, Inc., a corporation organized under the laws of the State of Delaware, having an address of 305 College Road East, Princeton, NJ 08540 (“Advaxis”) is made on the date set forth above (the “Effective Date”).
AMENDMENT TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • March 13th, 2009 • Noven Pharmaceuticals Inc • Pharmaceutical preparations
THIS AMENDMENT TO THE DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT (the “Amendment”) is entered into as of the 23rd day of December 2008, by and between Banner Pharmacaps Inc., a Delaware corporation (“Banner”), and Noven Therapeutics, LLC, (f/k/a JDS Pharmaceuticals, LLC, (“Noven”), a Delaware limited liability corporation.
DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT Dated as of June 5, 2000 Between EURAND AMERICA, INC. 845 Center Drive Vandalia, Ohio 45377 And RELIANT PHARMACEUTICALS 125 West 55th Street, 11th floor New York, NY 10019 For PROPRANOLOL MODIFIED RELEASE...Development, License and Supply Agreement • May 1st, 2007 • Eurand N.V. • New York
THIS DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT, dated as of June 5, 2000, between EURAND AMERICA, INC., a corporation organized under the laws of Nevada, with its principal offices at 845 Center Drive, Vandalia, Ohio 45377 (“EURAND”), and RELIANT PHARMACEUTICALS, INC., a corporation organized under the laws of the State of Delaware, with its principal offices at 721 Route 202/206 South, Bridgewater, New Jersey 08807 (“RELIANT”);
